Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Year: 2026
Type: article
Study design: Clinical Trial
Source: New England Journal of Medicine
Authors: Steven D. Nathan, Peter Smith, Chunqin Deng, Christopher S. King, Maria De Salvo, S. Samuel Weigt, Sahil Pandya, Debabrata Bandyopadhyay, Joseph A. Lasky, Rachana Krishna, Nathan Hambly, Murali Ramaswamy, Jad Kebbe, Neil Ettinger, Jamie Gao, Youlan Rao, Natalie Breytenbach, Leigh Peterson, Heidi Bell, Juergen Behr, Vincent Cottin, Kevin R. Flaherty
Institutions: Inova Fairfax Hospital, United Therapeutics (United States), University of California, Los Angeles, University of Kansas Medical Center, University of South Florida, Tulane University, Medical University of South Carolina, McMaster University, Cone Health, University of Oklahoma Health Sciences Center, LMU Klinikum, German Center for Lung Research, Ludwig-Maximilians-Universität München, Lyon 1 Université, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Hospices Civils de Lyon, University of Michigan, Michigan Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: United Therapeutics Corporation
OpenAlex ID: W7161607192